Heterologous ChAdOx1 and Bnt162b2 vaccination induces strong neutralizing antibody responses against SARS-CoV-2 including delta variant with tolerable reactogenicityopen access
- Authors
- Bae, S.[Bae, S.]; Ko, J.-H.[Ko, J.-H.]; Choi, J.-Y.[Choi, J.-Y.]; Park, W.-J.[Park, W.-J.]; Lim, S.Y.[Lim, S.Y.]; Ahn, J.Y.[Ahn, J.Y.]; Song, K.-H.[Song, K.-H.]; Lee, K.H.[Lee, K.H.]; Song, Y.G.[Song, Y.G.]; Chan, Kim Y.[Chan, Kim Y.]; Park, Y.S.[Park, Y.S.]; Choi, W.S.[Choi, W.S.]; Jeong, H.W.[Jeong, H.W.]; Kim, S.-W.[Kim, S.-W.]; Kwon, K.T.[Kwon, K.T.]; Kang, E.-S.[Kang, E.-S.]; Kim, A.-R.[Kim, A.-R.]; Jang, S.[Jang, S.]; Kim, B.[Kim, B.]; Kim, S.S.[Kim, S.S.]; Jang, H.-C.[Jang, H.-C.]; Choi, J.Y.[Choi, J.Y.]; Kim, S.-H.[Kim, S.-H.]; Peck, K.R.[Peck, K.R.]
- Issue Date
- Oct-2022
- Publisher
- Elsevier B.V.
- Keywords
- BNT162b2; ChAdOx1; COVID-19; Heterologous vaccination; SARS-CoV-2
- Citation
- Clinical Microbiology and Infection, v.28, no.10, pp.1390.e1 - 1390.e7
- Indexed
- SCIE
SCOPUS
- Journal Title
- Clinical Microbiology and Infection
- Volume
- 28
- Number
- 10
- Start Page
- 1390.e1
- End Page
- 1390.e7
- URI
- https://scholarworks.bwise.kr/skku/handle/2021.sw.skku/99842
- DOI
- 10.1016/j.cmi.2022.04.019
- ISSN
- 1198-743X
- Abstract
- Objectives: We assessed humoral responses and reactogenicity following the heterologous vaccination compared to the homologous vaccination groups. Methods: We enrolled healthcare workers (HCWs) who were either vaccinated with ChAdOx1 followed by BNT162b2 (heterologous group) or 2 doses of ChAdOx1 (ChAdOx1 group) or BNT162b2 (BNT162b2 group). Immunogenicity was assessed by measuring antibody titers against receptor-binding domain (RBD) of SARS-CoV-2 spike protein in all participants and neutralizing antibody titer in 100 participants per group. Reactogenicity was evaluated by a questionnaire-based survey. Results: We enrolled 499 HCWs (ChAdOx1, n = 199; BNT162b2, n = 200; heterologous ChAdOx1/BNT162b2, n = 100). The geometric mean titer of anti–receptor-binding domain antibody at 14 days after the booster dose was significantly higher in the heterologous group (11 780.55 binding antibody unit (BAU)/mL [95% CI, 10 891.52–12 742.14]) than in the ChAdOx1 (1561.51 [95% CI, 1415.03–1723.15]) or BNT162b2 (2895.90 [95% CI, 2664.01–3147.98]) groups (both p < 0.001). The neutralizing antibody titer of the heterologous group (geometric mean ND50, 2367.74 [95% CI, 1970.03–2845.74]) was comparable to that of the BNT162b2 group (2118.63 [95% CI, 1755.88–2556.32]; p > 0.05) but higher than that of the ChAdOx1 group (391.77 [95% CI, 326.16–470.59]; p < 0.001). Compared with those against wild-type SARS-CoV-2, the geometric mean neutralizing antibody titers against the Delta variant at 14 days after the boosting were reduced by 3.0-fold in the heterologous group (geometric mean ND50, 872.01 [95% CI, 685.33–1109.54]), 4.0-fold in the BNT162b2 group (337.93 [95% CI, 262.78–434.57]), and 3.2-fold in the ChAdOx1 group (206.61 [95% CI, 144.05–296.34]). The local or systemic reactogenicity after the booster dose in the heterologous group was higher than that of the ChAdOx1 group but comparable to that of the BNT162b2 group. Discussion: Heterologous ChAdOx1 followed by BNT162b2 vaccination with a 12-week interval induced a robust humoral immune response against SARS-CoV-2, including the Delta variant, that was comparable to the homologous BNT162b2 vaccination and stronger than the homologous ChAdOx1 vaccination, with a tolerable reactogenicity profile. © 2022 European Society of Clinical Microbiology and Infectious Diseases
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - Medicine > Department of Medicine > 1. Journal Articles
![qrcode](https://api.qrserver.com/v1/create-qr-code/?size=55x55&data=https://scholarworks.bwise.kr/skku/handle/2021.sw.skku/99842)
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.